Introduction
============

Chemotherapy is widely used in the field of cancer therapy. Multidrug resistance (MDR) is one of the major obstacles in the failure of cancer chemotherapy [@B1]. Several mechanisms, including insufficient accumulation at tumors, decreased drug uptake, increased drug efflux, metabolic detoxification and DNA repair were reported to be involved in the MDR in cancer [@B2]-[@B4]. Reversing the drug resistance remains a big challenge in cancer therapy.

Hyperthermia as a non-invasive clinical treatment modality exhibits competitive advantages in overcoming MDR in cancer [@B5]-[@B7]. Hyperthermia not only enhances tumor vascular permeability to promote the delivery of anticancer drug to deep tumor tissues [@B8]-[@B10], but also increases the sensitivity of resistant cancer cells to chemotherapeutic drugs by inhibiting the expression of efflux transporters such as multidrug resistance-associated protein 1 (MRP1) [@B7],[@B11]. Therefore, combining the hyperthermia and chemotherapy is a promising strategy for efficient cancer treatment with MDR reversal [@B12]. Gold nanocages (GNCs) have been used as a good photothermal (PTT)-chemotherapy integration platform due to their unique hollow interior and porous wall structure, high photothermal conversion efficiency and excellent biocompatibility [@B13]-[@B15]. However, the insufficient tumor cell internalization and premature drug leakage limit the anticancer activity of GNCs-based drug delivery systems [@B16],[@B17]. Although several strategies have been used to solve these problems, including conjugating GNCs with ligands that actively bind to surface receptors overexpressed in tumor cells to increase their tumor accumulation [@B18],[@B19], and modification of GNCs with thermally responsive polymers to block the pore outlets to avoid the *in vivo* premature drug release [@B20],[@B21], *et al*, some issues still remain in GNCs-based drug carriers. For example, the targeting ligand was not specific for cancer cells, which might result in the toxicity to normal cells [@B22]. Meanwhile, the targeting moieties on the surface of nanoparticles induce protein adsorption, thus affecting their circulation time and lowering their capacity to passively accumulate in tumors by enhanced permeation and retention (EPR) effects [@B22].

The pH low insertion peptide (pHLIP), a peptide of 36 amino acids, should be a good candidate to be used for the modification of nanoparticles for enhanced tumor cell internalization. pHLIP undergoes a conformational transition from random coil to α-helix in response to weakly acidic tumor microenvironment, allowing it to insert into tumor cell membranes with the C-terminus inside cells and the N-terminus outside cells [@B23],[@B24]. In this paper, we constructed a GNCs-based PTT-chemotherapy integration platform to reverse MDR in cancer (**Figure [1](#F1){ref-type="fig"}**), in which GNCs were conjugated with a thermoresponsive poly(di(ethylene glycol) methyl ether methacrylate-*co*-oligo(ethylene glycol) methyl ether methacrylate) (PMEO~2~MA-OEGMA) polymer (**Figure [1](#F1){ref-type="fig"}A**) and further modified with pH-sensitive pHLIP through Au-S bonds (denoted as pPGNCs), and the anticancer drug doxorubicin (DOX) was then highly loaded to pPGNCs (denoted as DOX\@pPGNCs) using ammonium sulfate gradient method (**Figure [1](#F1){ref-type="fig"}B**). pHLIP endows DOX\@pPGNCs to be efficiently internalized into cancer cells at the tumor acidic microenvironment (**Figure [1](#F1){ref-type="fig"}B-C**). As a new thermoresponsive polymer, PMEO~2~MA-OEGMA shows better biocompatibility, more feasible and sensitive thermoresponsiveness than poly(*N*-isopropylacrilamide), a well-known thermoresponsive polymer [@B25]-[@B27]. The hydrophilic nature of PMEO~2~MA-OEGMA ensures long blood circulation time of GNCs by preventing the opsonization via the reticuloendothelial system. By changing the feeding ratio of two monomers in the polymerization process, the lower critical solution temperature (LCST) of PMEO~2~MA-OEGMA could be rationally adjusted to ca. 41.6 ^o^C, between the body temperature and hyperthermia temperature, thus serving as a temperature sensitive gate keeper. That is, the chains of PMEO~2~MA-OEGMA polymer are extended at the body temperature, blocking the pore outlets of GNCs to avoid the premature drug release in blood circulation. When the temperature increases up to the LCST of PMEO~2~MA-OEGMA owing to the NIR laser-triggered photothermal effects of GNCs at the tumor tissues, its chains shrink as temperature sensitive coil-granule conformation transition occurs, resulting in the opening of the pores of GNCs and a rapid intracellular drug release (**Figure [1](#F1){ref-type="fig"}B-C**). Meanwhile, NIR laser irradiation at the tumor tissues markedly improves tumor accumulation and penetration of DOX\@pPGNCs (**Figure [1](#F1){ref-type="fig"}C**). The obtained DOX\@pPGNCs efficiently surmount a series of physiological barriers of anticancer drug following systemic administration, achieving synergized thermo-chemotherapy and excellent antitumor effect in adriamycin-resistant tumor model.

Results and Discussion
======================

Preparation and characterization of pPGNCs
------------------------------------------

To construct the temperature sensitive pHLIP-decorated GNCs, PMEO~2~MA~x~-OEGMA~200-x~ polymer was firstly synthesized. It was known that the LCST of temperature-responsive copolymers could be adjusted by changing the ratio of the monomers [@B28]. Three polymers with different LCSTs that were PMEO~2~MA~160~-OEGMA~40~, PMEO~2~MA~120~-OEGMA~80~ and PMEO~2~MA~80~-OEGMA~120~ (denoted as P~L~OEG, POEG and P~H~OEG, respectively) were synthesized by changing the molar ratio of MEO~2~MA and OEGMA. The successful synthesis was confirmed by ^1^H-NMR spectra (**Figure [S1](#SM0){ref-type="supplementary-material"}**). Gel permeation chromatography (GPC) analysis showed that the molecular weight of P~L~OEG, POEG and P~H~OEG were 41.1, 48.8 and 53.7 kDa (**Figure [2](#F2){ref-type="fig"}A, Figure [S2](#SM0){ref-type="supplementary-material"}A and Table [S1](#SM0){ref-type="supplementary-material"}**), consistent with their theoretic values. P~L~OEG, POEG and P~H~OEG exhibited the thermosensitive property and their LCSTs were calculated to be 31.6, 41.6 and 52.2 °C (**Figure [2](#F2){ref-type="fig"}B and Figure [S2](#SM0){ref-type="supplementary-material"}B**), respectively, suggesting that these polymers are hydrophilic and keep stretched chain conformation below their LCST, while turning into hydrophobic and shrunken chain conformation as temperature raises to above their LCST.

Subsequently, GNCs were synthesized through galvanic replacement reaction using silver nanocube templates. PMEO~2~MA-OEGMA~2~-based polymer~,~ including P~L~OEG, POEG or P~H~OEG, and pHLIP was anchored to GNCs through Au-S bonds to obtain PMEO~2~MA-OEGMA- and pHLIP-decorated GNCs (denoted as pP~L~GNCs, pPGNCs or pP~H~GNCs, respectively). High-resolution transmission electron microscopy (HR-TEM) showed that GNCs, POEG-conjugated GNCs (denoted as PGNCs) and pPGNCs possessed cube-shaped morphology (**Figure [3](#F3){ref-type="fig"}A**). HR-TEM analysis in combination with STEM/energy dispersive X-ray (EDX) elemental mapping revealed that only oxygen and carbon elements were detected on PGNCs, while nitrogen, oxygen and carbon elements were detected on pPGNCs (**Figure [3](#F3){ref-type="fig"}A**). In contrast, no nitrogen, oxygen and carbon elements existed on bare GNCs (**Figure [3](#F3){ref-type="fig"}A**). These results indicated that both POEG and pHLIP were conjugated to GNCs in pPGNCs. Furthermore, fluorescence emission spectra analysis showed that the emission peak of pHLIP at 344 nm was detected in pPGNCs (**Figure [3](#F3){ref-type="fig"}B**). In addition, there was no obvious difference in circular dichroism (CD) spectra of pHLIP and pPGNCs (**Figure [3](#F3){ref-type="fig"}C**). These results further confirmed that pHLIP was successfully anchored to GNCs and maintained its intact secondary structure after conjugation. Thermogravimetric analysis (TGA) of POEG, bare GNCs, PGNCs and pPGNCs revealed that 18.3% polymers and 5.9% pHLIP exhibited on pPGNCs (**Figure [3](#F3){ref-type="fig"}D**), indicating that there were about 42000 pHLIP molecules on a GNC particle.

To determine whether conjugation of PMEO~2~MA-OEGMA and pHLIP to GNCs affected their thermoresponsive property, pPGNCs, pP~L~GNCs or pP~H~GNCs were incubated in PBS at different temperatures and their diameters were then determined by DLS analysis (**Figure [3](#F3){ref-type="fig"}E**). No significant change in the diameter of GNCs was detected at different temperatures. However, the diameter of pPGNCs remarkably decreased after incubation in PBS at above 42 °C, while their diameter returned from 140 to 160 nm after decreasing temperature from 44 to 41 °C. These results suggested that pPGNCs preserved the thermosensitive property and POEG chains shrank on pPGNCs above its LCST of 41.6 °C. In contrast, the diameter of pP~H~GNCs remained unchanged at temperatures from 25 to 44 °C (the LCST of P~H~OEG was 52.2 °C), and the diameter of pP~L~GNCs decreased from 30 to 33 °C and increased from 33 to 30 °C (the LCST of P~L~OEG was 31.6 °C, **Figure [S2](#SM0){ref-type="supplementary-material"}C**).

NIR laser-triggered on-demand DOX release from DOX\@pPGNCs
----------------------------------------------------------

Anticancer drug DOX was then loaded into pPGNCs, pP~L~GNCs or pP~H~GNCs by ammonium sulfate gradient method [@B16],[@B29]. Conjugation of POEG polymer increased the diameter and decreased the zeta-potential of GNCs (**Figure [4](#F4){ref-type="fig"}A**). However, DOX loading did not markedly affect the diameter and zeta-potential of pPGNCs (**Figure [4](#F4){ref-type="fig"}A**). UV-Vis-NIR spectra analysis showed that conjugation of POEG and pHLIP and loading DOX did not affect the absorption of GNCs. However, NIR laser irradiation increased DOX absorption of DOX\@pPGNCs (**Figure [S3](#SM0){ref-type="supplementary-material"}**), suggesting that DOX was loaded into the hollow cavity of GNCs rather than adsorbing on the surface. Moreover, TEM analysis showed that there was no significant morphology change after DOX loading into pPGNCs (**Figure [4](#F4){ref-type="fig"}B**). The drug loading of pPGNCs was calculated to be 11.3%.

To determine whether GNCs preserved photothermal effects after modification with POEG and pHLIP and the subsequent DOX loading, GNCs, PGNCs, pPGNCs, DOX\@PGNCs and DOX\@pPGNCs were irradiated with NIR laser (808 nm, 0.7 W/cm^2^) and their temperatures were then examined (**Figure [4](#F4){ref-type="fig"}C**). GNCs, PGNCs, pPGNCs, DOX\@PGNCs and DOX\@pPGNCs exhibited very similar temperature profiles. Their temperatures quickly increased up to 53 °C after irradiation for 5 min, although the temperature of PBS only increased to 27.5 °C after irradiation. These results revealed that POEG and pHLIP modification and DOX loading did not influence the photothermal activity of GNCs. Moreover, the temperature profile of DOX\@pPGNCs upon NIR laser irradiation did not change even going through five irradiation-cooling cycles (**Figure [4](#F4){ref-type="fig"}D**). Meanwhile, NIR laser irradiation five times did not affect the morphology (**Figure [S4](#SM0){ref-type="supplementary-material"}**), size (**Figure [S5](#SM0){ref-type="supplementary-material"}A**), zeta potential (**Figure [S5](#SM0){ref-type="supplementary-material"}B**) and UV-Vis-NIR spectra (**Figure [S3](#SM0){ref-type="supplementary-material"}**) of DOX\@pPGNCS, revealing their good photothermal stability.

To evaluate the effects of NIR laser-induced photothermal therapy on the characterization of DOX\@pPGNCs, the diameter of DOX\@pPGNCs was first measured upon NIR laser irradiation at 37 °C (**Figure [4](#F4){ref-type="fig"}E**). As expected, the diameter of PGNCs, pPGNCs, DOX\@PGNCs and DOX\@pPGNCs rapidly decreased after irradiation for 1 min, which was due to the shrinkage of POEG chains induced by NIR laser-triggered photothermal effects above their LCST. In contrast, NIR irradiation had no remarkable influence on the diameters of DOX\@pP~H~GNCs and DOX\@pP~L~GNCs (**Figure [S6](#SM0){ref-type="supplementary-material"}A**). The reason was that no phase-transition occurred for pP~L~GNCs and pP~H~GNCs during NIR irradiation, in which P~L~OEG chains always collapsed on pP~L~GNCs above its LCST and P~H~OEG chains always stretched on pP~H~GNCs below its LCST before and after NIR irradiation. These results suggested that the shrinkage of POEG upon NIR laser-induced photothermal effects might induce the pore opening of GNCs in DOX\@pPGNCs, resulting in NIR laser-induced on-demand drug release.

To confirm NIR laser-triggered photothermal drug release from DOX\@pPGNCs, the *in vitro* DOX release kinetics from DOX\@pPGNCs was carried out in PBS with or without NIR laser irradiation (**Figure [4](#F4){ref-type="fig"}F**). Only 4.8% DOX was released within 4 h at 37 °C in the absence of NIR laser irradiation. However, the cumulative DOX release increased from 3.7 to 20.1% upon 808 nm laser irradiation for 5 min during 1 h. Furthermore, rapid DOX release was consistently observed upon 808 nm laser irradiation in another cycle. These results revealed that DOX\@pPGNCs were stable under physiological condition and precisely released drug upon NIR laser irradiation. In contrast, 76.7% DOX was released from DOX\@pP~L~GNCs and only 5.6% DOX was released from DOX\@pP~H~GNCs at 37 °C without NIR laser irradiation (**Figure [S6](#SM0){ref-type="supplementary-material"}B**). NIR laser irradiation did not significantly affect DOX release from DOX\@pP~L~GNCs and DOX\@pP~H~GNCs (**Figure [S6](#SM0){ref-type="supplementary-material"}B**). These results demonstrate that POEG function as a gatekeeper of GNCs to control NIR laser-triggered precise on-demand DOX release from DOX\@pPGNCs.

Cellular uptake and synergistic cytotoxicity of DOX\@pPGNCs*in vitro*
---------------------------------------------------------------------

To determine the biological function of DOX\@pPGNC, the cellular uptake of DOX\@pPGNCs by sensitive human breast cancer MCF-7 cells and adriamycin-resistant MCF-7 (MCF-7/ADR) cells was evaluated. MCF-7 or MCF-7/ADR cells were incubated with DOX\@PGNCs or DOX\@pPGNCs at pH 7.4 or 6.5 for 4 h and then the intracellular Au contents were determined by graphite furnace atomic absorption spectrometry (**Figure [5](#F5){ref-type="fig"}A-B**). There was no significant difference in cellular uptake of DOX\@PGNCs and DOX\@pPGNCs by MCF-7 and MCF-7/ADR cells at pH 7.4. However, significantly enhanced intracellular accumulation of DOX\@pPGNCs was detected in MCF-7 and MCF-7/ADR cells at pH 6.5 compared with DOX\@PGNCs. Similar results were also found in human hepatocellular carcinoma HepG2 cells and adriamycin-resistant HepG2/ADM cells (**Figure [5](#F5){ref-type="fig"}C-D**). These results suggest that pHLIP coating increased the cellular uptake of DOX\@pPGNCs by cancer cells under acidic pH environment. The reason might be that the increase in α-helix content of pHLIP at acidic pH environment contributed to the enhanced cellular uptake of DOX\@pPGNCs, as evidenced by the more α-helix content (**Figure [S7](#SM0){ref-type="supplementary-material"}A and Table [S2](#SM0){ref-type="supplementary-material"}**) and correspondingly more cellular internalization (**Figure [S7](#SM0){ref-type="supplementary-material"}B**) of DOX\@pPGNCs at acidic pH values. Macropinocytosis-, caveolin- and clathrin-medicated endocytosis was involved in the internalization of DOX\@pPGNCs and DOX\@PGNCs (**Figure [S8](#SM0){ref-type="supplementary-material"}**).

To investigate the synergistic anticancer activity of DOX\@pPGNCs from photothermal therapy of GNCs and DOX chemotherapy, MCF-7 or MCF-7/ADR cells were treated with free DOX, GNCs, PGNCs, pPGNCs, DOX\@PGNCs or DOX\@pPGNCs for 24 h, followed with or without 808 nm laser irradiation for 5 min, the*in vitro* cytotoxicity was then evaluated by MTT assay (**Figure [5](#F5){ref-type="fig"}E-F**). Free DOX induced stronger cytotoxicity against MCF-7 cells than MCF-7/ADR cells, confirming the drug resistance of MCF-7/ADR cells. NIR laser irradiation significantly increased the cytotoxicity of PGNCs and pPGNCs against MCF-7 and MCF-7/ADR cells at both pH 7.4 and 6.5. Meanwhile, DOX\@PGNCs and DOX\@pPGNCs further enhanced the cytotoxicity against MCF-7 and MCF-7/ADR cells in response to NIR laser irradiation compared with PGNCs and pPGNCs, suggesting the synergistic effects of thermo-chemotherapy. However, the cytotoxicity of pPGNCs and DOX\@pPGNCs against MCF-7 and MCF-7/ADR cells upon NIR laser irradiation at pH 6.5 was stronger than that at pH 7.4. DOX\@pPGNCs exhibited the strongest cytotoxicity against MCF-7 and MCF-7/ADR cells upon NIR laser irradiation at pH 6.5. These results confirmed that pHLIP conjugation increased the internalization of DOX\@pPGNCs into cancer cells under tumor acidic microenvironment, and DOX\@pPGNCs upon NIR laser irradiation could generate effective synergistic thermo-chemotherapy with MDR reversal.

NIR Laser-Induced Intracellular Drug Release of DOX\@pPGNCs
-----------------------------------------------------------

In view that NIR laser induced on-demand anticancer drug release from DOX\@pPGNCs, the intracellular drug release of DOX\@pPGNCs upon NIR laser irradiation was determined in MCF-7/ADR cells. MCF-7/ADR cells were treated with DOX\@PGNCs or DOX\@pPGNCs for 4 h at pH 7.4 or 6.5, washed with PBS, and then irradiated with 808 nm laser for 5 min. Intracellular DOX fluorescence was detected by confocal microscope and flow cytometry. Confocal microscopic images showed that NIR laser irradiation increased the intracellular DOX fluorescence of DOX\@PGNCs and DOX\@pPGNCs at both pH 7.4 and 6.5 (**Figure [6](#F6){ref-type="fig"}A**), revealing the NIR laser-induced photothermal effects resulted in intracellular drug release from DOX\@pPGNCs. However, no significant difference was detected in DOX\@PGNCs-treated group upon NIR laser irradiation at pH 7.4 and 6.5, while stronger intracellular DOX fluorescence and more DOX nuclear translocation were found in DOX\@pPGNCs-treated group in response to NIR irradiation at pH 6.5 than that at pH 7.4, even better than DOX\@PGNCs-treated group upon NIR irradiation at pH 6.5 (**Figure [6](#F6){ref-type="fig"}A**). The qualitative results from confocal microscope were further confirmed by the quantitative results obtained from flow cytometry (**Figure [6](#F6){ref-type="fig"}B-C**). These results further revealed that pHLIP coating increased the cellular uptake of DOX\@pPGNCs under tumor acidic microenvironment, and DOX was efficiently released and then translocated to nucleus in response to NIR laser-induced photothermal effects.

NIR laser-induced tumor accumulation and penetration of DOX\@pPGNCs
-------------------------------------------------------------------

It has been widely acknowledged that*in vivo* biodistribution of anticancer drugs affects their therapeutical efficacy and potential side effects [@B30],[@B31]. To detect the biodistribution of DOX\@pPGNCs, MCF-7/ADR tumor-bearing nude mice were intravenously injected with free DOX, DOX\@PGNCs or DOX\@pPGNCs, followed with or without 808 nm laser irradiation for 5 min. At 24 h after administration, the mice were executed, and DOX contents in major organs (heart, liver, spleen, lung and kidney) and tumors were determined. As shown in**Figure [7](#F7){ref-type="fig"}A**, DOX\@pPGNCs and DOX\@PGNCs with or without NIR laser irradiation exhibited nearly 2 fold lower DOX accumulation in the heart tissues than free DOX, indicating that DOX\@pPGNCs and DOX\@PGNCs might have ability to reduce DOX cardiotoxicity compared with free DOX. Conversely, DOX content in tumor tissues of mice treated with DOX\@PGNC was nearly 1.8 times of free DOX, which might be due to EPR effects of DOX\@PGNCs. However, DOX\@pPGNCs exhibited the highest DOX accumulation in tumors compared with DOX\@PGNCs and DOX due to the enhanced tumor cell internalization of pHLIP. Moreover, DOX accumulation of DOX\@PGNCs and DOX\@pPGNsC in the tumors enhanced significantly upon irradiation with NIR laser, revealing that NIR laser-induced photothermal effects of GNCs further increased their tumor accumulation.

Due to the abnormal vascular structure, increased interstitial fluid pressure and compact extracellular matrix in tumor tissues, nanoparticles are majorly accumulated near the tumor blood vessels, thus decreasing the opportunity of delivering anticancer drugs to cancer cells [@B32]-[@B34]. Improving the tumor penetration capacity of nanoparticles was crucial for increasing the therapeutic efficacy. To evaluate their tumor penetration ability, MCF-7/ADR tumor-bearing nude mice were intravenously injected with free DOX, DOX\@PGNCs or DOX\@pPGNCs, followed with or without 808 nm laser irradiation for 5 min. At 24 h after injection, DOX fluorescence in tumor sections was evaluated by confocal microscope (**Figure [7](#F7){ref-type="fig"}B-C**). Consistent with the tumor accumulation data, NIR laser irradiation significantly increased DOX fluorescence in tumors of DOX\@PGNCs- and DOX\@pPGNCs-treated mice, and DOX\@pPGNCs exhibited the strongest DOX fluorescence in tumors upon NIR laser irradiation, confirming that pHLIP coating increased tumor accumulation of DOX\@pPGNCs and NIR laser irradiation further increased their tumor accumulation. Meanwhile, compared with other group, DOX fluorescence was scattered throughout the entire tumor section in DOX\@pPGNCs-treated mice in the presence of NIR laser irradiation, rarely colocalized with fluorescein isothiocyanate isomer I (FITC)-labeled CD31, a blood vasculature endothelial cell marker. These results revealed that NIR laser induced excellent tumor penetration ability of DOX\@pPGNCs.

*In vivo* photothermal effects of DOX\@pPGNCs
---------------------------------------------

In view of the enhanced tumor accumulation of DOX\@pPGNCs, the *in vivo* phototheraml effects were measured in MCF-7/ADR tumor-bearing nude mice (**Figure [8](#F8){ref-type="fig"}A-B**). The mice were intravenously administrated with free DOX, GNCs, PGNCs, pPGNCs, DOX\@PGNCs or DOX\@pPGNCs. At 24 h after administration, the tumor tissues were irradiated with NIR laser for different time intervals and their temperature was detected by an IR camera. Consistently, the irradiated tumor tissues of pPGNCs- and DOX\@pPGNCs-treated mice exhibited a significant temperature increase compared with those of GNCs-, PGNCs- and DOX\@PGNCs-treated mice, which might be due to their enhanced tumor accumulation capacity. The maximal temperature of the irradiated tumor tissues in pPGNCs- and DOX\@pPGNCs-treated mice can reach 49.6 °C, high enough to kill cancer cells. However, the temperature only increased by about 3 °C in the irradiated tumors of free DOX-treated mice.

*In vivo* synergistic thermo-chemotherapeutic activity of DOX\@pPGNCs in MCF-7/ADR tumor-bearing mice
-----------------------------------------------------------------------------------------------------

Considering NIR laser-induced elevated temperature for photothermal therapy and enhanced DOX accumulation and penetration in tumor tissues, cellular uptake by cancer cells and on-demand intracellular drug release, the*in vivo* anticancer activity of DOX\@pPGNCs was evaluated in MCF-7/ADR tumor-bearing nude mice (**Figure [9](#F9){ref-type="fig"}A**), intravenous injection of free DOX did not induce significant tumor inhibition, confirming the successful construction of drug-resistant tumor model. NIR laser irradiation did not affect the anticancer efficacy of DOX, suggesting that NIR laser itself did not generate the photothermal anticancer activity. Even though PGNCs and pPGNCs achieved enhanced anticancer activity upon NIR laser irradiation, the anticancer activity of pPGNCs upon NIR laser irradiation was stronger than PGNCs upon NIR irradiation, which was due to the enhanced tumor accumulation after pHLIP coating. DOX\@pPGNCs exhibited the strongest anticancer activity with a tumor inhibition rate of 97.3% (2 mice undergoing tumor ablation in 5 mice), suggesting the synergistic effects of thermo-chemotherapy in drug-resistant MCF-7/ADR tumor-bearing mice. The tumor weight excised at the end of treatment also showed the same trend (**Figure [9](#F9){ref-type="fig"}B-C**).

To test the biosafety of DOX\@pPGNCs, body weight, an important indicator of general systemic toxicity, was evaluated during treatment. No significant difference in body weight was found in mice administrated with free DOX, DOX\@PGNCs or DOX\@pPGNCs with or without NIR laser irradiation (**Figure [9](#F9){ref-type="fig"}D**). Meanwhile, the histopathological examinations of the major organs were performed by H&E staining (**Figure [S9](#SM0){ref-type="supplementary-material"}**). All treatment groups did not show obvious pathological changes in heart, liver, spleen, lung and kidney. These results revealed that DOX\@pPGNCs were capable of overcoming MDR and exhibited stronger anticancer activity with few adverse effects.

Conclusions
===========

In summary, we have successfully fabricated thermoresponsive POEG- and pH-sensitive pHLIP-conjugated GNCs for DOX delivery to reverse MDR in cancer. DOX\@pPGNCs display good photothermal efficacy and on-demand drug release. NIR laser-trigged photothermal effects induce the enhanced tumor accumulation and penetration of DOX\@pPGNCs. After accumulation at tumor sites, DOX\@pPGNCs are efficiently internalized into drug-resistant cancer cells by responding to the acidic tumor microenvironment. DOX\@pPGNCs are stable in the blood circulation, while NIR laser irradiation at the tumor sites contributes to the shrinkage of POEG and facilitates the intracellular DOX release to enter into the nuclei, exhibiting the synergistic photothermal and chemotherapeutic cytotoxicity against drug-resistant cancer cells. Therefore, excellent *in vivo* tumor inhibition efficacy of DOX\@pPGNCs was achieved in MCF-7/ADR tumor-bearing mice with no obvious side effects. This finding provides a new synergistic strategy to acquire the ideal therapeutic effects in cancer treatment with MDR reversal.

Materials and Methods
=====================

Materials
---------

MEO~2~MA, OEGMA, bis\[2-(2′-broMoisobutyryloxy)-ethyl\]disulfide (BiBOEDS), silver trifluoroacetate (CF~3~COOAg) and poly(vinylpyrrolidone) (PVP, M~w~=55kD) were obtained from Sigma-Aldrich Corp (St Louis, MO, USA). Tris(2-dimethyl-aminoethyl)amine (Me~6~TREN) and anhydrous sodium hydrosulfide (NaHS) were purchased from Alfa Aesar (Shanghai, China). Ethylene glycol (EG, purity\>99.0%), cuprous chloride (CuCl), chloroauric acid hydrate (HAuCl~4~·4H~2~O, Au content\>47.8%) and 4\'6-diamidino-2-phenylindole (DAPI) were purchased from Sinopharm Chemical Reagent Co., Ltd (Beijing, China). DMEM, RPMI 1640 and fetal bovine serum (FBS) were obtained from Gibco BRL/Life Technologies (Grand Island, NY, USA). pHLIP (ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT) was synthesized by Bankpeptide Inc. (Heifei, China). All other reagents were of analytical grade and used without any further purification.

Synthesis of GNCs
-----------------

GNCs were synthesized through galvanic replacement reaction between Ag nanocubes and HAuCl~4~ [@B16],[@B35]. Briefly, Ag nanocubes were first synthesized as follows. 50 mL of ethylene glycol was heated in 150 °C oil-bath for 30 min. Then 0.6 mL of NaHS solution in ethylene glycol (0.3 mM) was mixed into hot ethylene glycol under vigorous stirring, followed by mixing 12.5 mL of PVP solution in ethylene glycol (20 mg/mL), 5 mL of HCl solution in ethylene glycol (3.0 mM) and 4.0 mL of CF~3~COOAg solution in ethylene glycol (282 mM). The reaction lasted for 45 min at 150 °C. The obtained Ag nanocubes were washed with acetone and deionized water to remove PVP and ethylene glycol. Subsequently, the refined Ag nanocubes were dispersed in deionized water.

Afterwards, 10 mL of Ag nanocubes (6.7 mM) was added to 90 mL of deionized water containing PVP (1.6 mg/mL) and heated to 90 °C for 10 min under vigorous stirring. Then 1.0 mM HAuCl~4~ solution was added using a micro-infusion pump (WZ-50C6, Zhejiang Smiths Medical Instrument Co, Ltd, China) at 42 mL/h of injection rate until the solution had an localized surface plasmon resonance (LSPR) peak at 808 nm measured by UV-Vis-NIR spectroscopy (TU 1901, Beijing Tongyong General Instrumental Co, Ltd., Beijing, China). The crude GNCs were collected by centrifugation at 10,000 rpm for 10 min and washed with ammonium hydroxide, absolute ethyl alcohol and deionized water, respectively. The refined GNCs were dispersed in deionized water and stored at 4 °C for further use.

Preparation of PMEO~2~MA*~x~*-OEGMA*~200-x~* with different LCSTs
-----------------------------------------------------------------

PMEO~2~MA*~x~*-OEGMA*~200-x~* (polymerization degree *x*=160, 120 or 80) with different LCSTs were synthesized according to atom transfer radical polymerization (ATRP) [@B36]. Taking *x* = 120 for example, MEO~2~MA (5.53 mL, 30 mmol), OEGMA (5.71 mL, 20 mmol) and absolute ethanol (10 mL) were mixed in a Schlenk tube under vigorous stirring. The reaction system was sequentially frozen by liquid nitrogen, vacuumed by a vacuum pump and argon-filling for one cycle. Afterwards, BiBOEDS (76 µL, 0.25 mmol) and Me~6~TREN (135 μL, 0.5 mmol) were added into the Schlenk tube under argon atmosphere. After two cycles of liquid nitrogen refrigeration, vacuum and argon-filling, CuCl (50 mg, 0.5 mmol) was added into the solvents to initiate ATRP polymerization. After reacting at 60 °C for 24 h, PMEO~2~MA*~x~*-OEGMA*~200-x~* was obtained. The crude PMEO~2~MA*~x~*-OEGMA*~200-x~* was transferred to dialysis bag (MWCO: 3500 Da) against deionized water for 3 days to remove the small molecular impurities. Eventually, the refined PMEO~2~MA*~x~*-OEGMA*~200-x~* was freeze-dried and stored in a vacuum desiccator for further use. The molecular structure and molar mass of PMEO~2~MA*~x~*- OEGMA*~200-x~* were measured by ^1^H-NMR spectrometer (600 MHz, AV400, Bruker, Switzerland) using CDCl~3~ as solvent and GPC (1100 LC/MSD Trap, Agilent, USA) using 0.1 mM sodium nitrate aqueous solution as eluent, respectively. The temperature-transmittance curve of PMEO~2~MA*~x~*-OEGMA*~200-x~* (2 mg/mL, in PBS buffer) was determined by UV-Vis spectrophotometer (UV-3600, Shimadzu, Japan) at a wavelength of 500 nm in the temperature range of 25 - 50 °C. Their LCST was calculated by taking the derivative with respect to Boltzmann fitting of the temperature-transmittance curve.

Preparation of PMEO~2~MA*~120~*-OEGMA*~80~*- and pHLIP-conjugated GNCs
----------------------------------------------------------------------

GNCs were sequentially decorated with temperature-sensitive PMEO~2~MA*~120~*-OEGMA*~80~*- and the N-terminus of the pHLIP. Briefly, 10 mL of PMEO~2~MA*~120~*-OEGMA*~80~* (50 mg/mL) was added dropwise to 1 mL of GNCs solution (10 mg/mL) under vigorous stirring. After reacting at room temperature for 3 days, the obtained PMEO~2~MA*~120~*-OEGMA*~80~*-conjugated GNCs (denoted as PGNCs) were collected by centrifugation at 10,000 rpm for 10 min and washed with deionized water. Then, the PGNCs were re-dispersed in 1 mL of deionized water. 5 mL of pHLIP (2 mg/mL) was added dropwise to the dispersion and the reaction was maintained for another 24 h. PMEO~2~MA*~120~*-OEGMA*~80~*- and pHLIP-conjugated GNCs (denoted as pPGNCs) were collected by centrifugation at 10,000 rpm for 10 min, washed with deionized water and stored at 4 °C for further use.

Remote loading DOX into PGNCs and pPGNCs
----------------------------------------

DOX was loaded into PGNCs and pPGNCs by ammonium sulfate gradient method [@B15],[@B28]. First, 0.5 mL of PGNCs and pPGNCs (10 mg/mL) were dispersed in 5.0 mL of ammonium sulfate solution (0.2 M) at 55 °C for 12 h. After 10 min of ultrasonic concussion, the dispersions were centrifuged at 12,000 rpm for 10 min at 4 °C and washed with deionized water for 3 times to remove unloaded ammonium sulfate. Afterwards, 2 mL of DOX solution (5 mg/mL) was added to ammonium sulfate-loaded PGNCs and pPGNCs and incubated at 4 °C for 12 h. DOX\@PGNCs and DOX\@pPGNCs were collected by centrifugation at 12,000 rpm for 10 min and washed with deionized water. The drug loading capacity (DLC) was calculated as the following equation: DLC%= (W~administered\ DOX~-C~f~V~f~/W~pPGNCs~)×100, where W~administered\ DOX~ is the feeding amount of DOX, C~f~ and V~f~ are the concentration and volume of free DOX not being encapsulated into pPGNCs, and W~pPGNCs~ is the amount of pPGNCs.

Characterization
----------------

The element distribution mapping of GNCs, PGNCs and pPGNCs was evaluated by HR-TEM (300 kV, Tecnai G2 F30, FEI Corp, USA). The fluorescence spectra of pHLIP, GNCs, PGNCs and pPGNCs were measured by fluorescence spectrophotometer (F4500, Hitachi Co., Japan). The CD spectra of different formulations were measured at room temperature using a CD spectrometer (J-810, Jasco, Japan). TGA of different formulations was conducted on the Diamond TG/DTA (PerkinElmer Instruments Co. Ltd., USA) from room temperature to 600 °C at a heating rate of 10 °C/min. The hydrodynamic diameter and zeta potential of GNCs, PGNCs, pPGNCs, DOX\@PGNCs and DOX\@pPGNCs at Au concentration of 10 µg/mL were determined by dynamic light scattering (DLS, Zetasizer Nano ZS90, Malvern Instruments Ltd, UK) equipped with 4 mW He-Ne laser source (λ = 633 nm, scattering angle 90 °) in deionized water. The UV-Vis-NIR spectra of GNCs, PGNCs, pPGNCs, DOX\@PGNCs and DOX\@pPGNCs were monitored by UV-Vis-NIR spectroscopy (TU 1901, Beijing Tongyong General Instrumental Co, Ltd., Beijing, China). The morphology of different formulations was determined by TEM (200 kV, Tecnai G2 20, FEI Corp., Netherlands).

*In vitro* photothermal effects
-------------------------------

PBS, GNCs, PGNCs, pPGNCs, DOX\@PGNCs or DOX\@pPGNCs dispersions in PBS at Au concentration of 10 μg/mL were irradiated with 808 nm laser at a power density of 0.7 W/cm^2^ for different time intervals. The temperature was measured by an FLIR E50 IR camera (FLIR Systems Inc., USA).

*In vitro* photothermal stability
---------------------------------

DOX\@pPGNCs dispersions in PBS at Au concentration of 10 μg/mL were irradiated with 808 nm laser at a power density of 0.7 W/cm^2^ for 10 min and then cooled at room temperature for 10 min. The irradiation-cooling cycles were repeated for five times and the temperature was measured by an FLIR E50 IR camera.

*In vitro* NIR laser-induced DOX release
----------------------------------------

DOX\@PGNCs or DOX\@pPGNCs dispersions at Au concentration of 10 μg/mL were irradiated with or without 808 nm laser at a power density of 0.7 W/cm^2^ for 5 min at the designated time intervals. DOX fluorescence in the supernatants was measured by fluorescence spectrometer.

Cell culture and animals
------------------------

MCF-7 and MCF-7/ADR cells were kindly provided by Prof. Zhiping Zhang in School of Pharmacy, Huazhong University of Science and Technology (Wuhan, China). HepG2 and HepG2/ADM cells were kindly provided by Prof. Yin Wan in College of Life Science and Technology, Huazhong University of Science and Technology (Wuhan, China). MCF-7 and MCF-7/ADR cells were cultured in RPMI 1640 medium, and HepG2 and HepG2/ADM cells were cultured in DMEM medium containing 10% FBS, 100 U/mL penicillin G sodium and 100 μg/mL streptomycin sulfate at 37 °C in a humidified and 5% CO~2~ incubator except adding 1 mg/mL DOX during MCF-7/ADR and HepG2/ADM cell culture.

Female nude mice (5 weeks, 16±2g) were provided by HUAFUKANG bioscience Co, LTD (Beijing, China). MCF-7/ADR tumor-bearing nude mice model was constructed by subcutaneously injecting 2×10^6^ MCF-7/ADR cells into the right back of the nude mice. All animal experiments were approved by the Institutional Animal Care and Use Committee at Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China).

Cellular uptake
---------------

MCF-7, MCF-7/ADR, HepG2 or HepG2/ADM cells were cultured in a 12-well plate at a density of 2 × 10^5^ cells per well. At 24 h after incubation, the cells were treated with DOX\@PGNCs or DOX\@pPGNCs at 10 μg/mL Au concentration for 12 h at pH 7.4, 6.5 or 6.0, respectively. Subsequently, the cells were washed with PBS and intracellular Au content was determined by graphite furnace atomic absorption spectrometry (AA-240FS, Agilent Technologies, Santa Clara, CA, USA).

NIR laser-induced intracellular drug release
--------------------------------------------

MCF-7 and MCF-7/ADR cells were cultured in a 12-well plate at a density of 2 × 10^5^ cells per well. At 24 h after incubation, the cells were treated with DOX\@PGNCs or DOX\@pPGNCs at 2 μg/mL DOX concentration for 4 h at pH 7.4 or 6.5, respectively, followed by irradiation with or without 808 nm NIR laser irradiation at a power density of 0.7 W/cm^2^ for 5 min. Intracellular DOX content was determined by flow cytometry (FC500, Beckman Coulter, Fullerton, CA, U.S.A.) and confocal microscope. For confocal microscopic analysis, the cells were stained with 2.5 μg/mL DAPI for 15 min at 37 °C and then observed by an Olympus FV1000 confocal microscope (Tokyo, Japan).

*In vitro* cytotoxicity
-----------------------

MCF-7 or MCF-7/ADR cells were treated with free DOX, GNCs, PGNCs, pPGNCs, DOX\@PGNCs or DOX\@pPGNCs at DOX concentration of 1.2 μg/mL and Au concentration of 10 μg/mL at pH 7.4 or 6.5, respectively. At 24 h after treatment, the cells were washed with PBS and then irradiated with or without 808 nm NIR laser at a power density of 0.7 W/cm^2^ for 5 min, followed by incubation for another 4 h. The cells were washed with PBS and then incubated in the media containing MTT solution (5 mg/mL) at 37 °C for another 4 h. The media were discarded and 150 μL DMSO was added to dissolve formazan crystals. The absorbance of formazan at 492 nm was measured by a Labsystems iEMS microplate reader (Helsinki, Finland).

*In vivo* biodistribution
-------------------------

MCF-7/ADR tumor-bearing nude mice were intravenously administrated with free DOX, DOX\@PGNCs or DOX\@pPGNCs at DOX dosage of 2.4 mg/kg, immediately followed with or without 808 nm laser irradiation at a power density of 0.7 W/cm^2^ for 5 min at tumor sites. At 24 h after injection, the major organs including heart, liver, spleen, lung, kidney and tumor were resected. These tissues were then washed with saline and homogenized with methanol and sonicated for 10 min at 45 °C. DOX content in the supernatants was measured by fluorescence spectrometer at the excitation wavelength of 488 nm and the emission wavelength of 560 nm.

*In vivo* tumor penetration
---------------------------

MCF-7/ADR tumor-bearing nude mice were intravenously administrated with free DOX, DOX\@PGNCs or DOX\@pPGNCs at the DOX dosage of 2.4 mg/kg, immediately followed with or without 808 nm laser irradiation at a power density of 0.7 W/cm^2^ for 5 min at tumor sites. At 24 h after administration, the tumor tissues were harvested, washed with PBS and then frozen sectioned. The sections were stained with FITC-conjugated CD31 antibody at 37 °C for 30 min, washed with PBS and then observed by confocal microscope. The distribution of DOX fluorescence from blood vessels to tumor tissues was analyzed by software image J 1.45S.

*In vivo* photothermal effect
-----------------------------

MCF-7/ADR tumor-bearing nude mice were intravenously administrated with PBS, DOX, GNCs, PGNCs, pPGNCs, DOX\@PGNCs or DOX\@pPGNCs at the Au dosage of 20 mg/kg., immediately followed with or without 808 nm laser irradiation at a power density of 0.7 W/cm^2^ for 5 min at tumor sites. At 24 h after administration, the tumor tissues of mice were irradiated with 808 nm laser at a power density of 0.7 W/cm^2^ for different time intervals. The temperature of the tumor tissues were detected by an FLIR E50 IR camera.

*In vivo* antitumor efficacy
----------------------------

MCF-7/ADR tumor-bearing nude mice were intravenously administrated with PBS, free DOX, GNCs, PGNCs, pPGNCs, DOX\@PGNCs or DOX\@pPGNCs at DOX dosage of 2.4 mg/kg and Au dosage of 20 mg/kg, immediately followed with or without 808 nm laser (0.7 W/cm^2^) irradiation for 5 min at tumor sites. The nude mice were further irradiated with or without 808 nm laser (0.7 W/cm^2^) for 5 min once every other day. Tumor sizes were monitored using a digital caliper every day and their volumes were calculated based on the formula: V=(L×W^2^)/2, where L and W are length and width of tumor, respectively. On day 15, the mice were sacrificed, and major organs including heart, liver, spleen, lung, kidney and tumor were excised, fixed and sliced for hematoxylin and eosin (H&E) staining.

Statistical analysis
--------------------

All experiments were performed with at least three replicates. Student\'s *t* test was used to carry out the statistical analyses. *p*\<0.05 was considered significant.
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![Schematic illustration of DOX\@pPGNCs for synergistic PTT-chemotherapy to reverse MDR in cancer. **(A)** Synthesis of POEG. (B) Construction and characterization of DOX\@pPGNCs. **(C)** Schematic illustration of the NIR laser-induced *in vivo* transport process of DOX\@pPGNCs.](thnov09p3825g001){#F1}

![Characterization of POEG. **(A)** GPC spectrum of POEG. **(B)** Transmittance of POEG at 500 nm after incubation in PBS at the indicated temperatures for 5 min. The data are presented as the mean ± SD (n = 3).](thnov09p3825g002){#F2}

![Characterization of pPGNCs. **(A)** Microstructure and element composition of GNCs, PGNCs and pPGNC. **(B)** Fluorescence spectra of GNCs, pHLIP, PGNCs and pPGNCs at the excitation wavelength of 280 nm. **(C)** CD spectra of GNCs, pHLIP, PGNCs and pPGNCs. **(D)** TGA analysis of POEG, GNCs, PGNCs and pPGNCs. (E) Diameter change of GNCs and pPGNCs incubating in PBS at the different temperatures. The data are presented as the mean ± SD (n = 3).](thnov09p3825g003){#F3}

![**NIR laser-triggered photothermal drug release from DOX\@pPGNCs. (A)** Diameter and zeta potential of GNCs, PGNCs, pPGNCs, DOX\@PGNCs and DOX\@pPGNCs. **(B)** TEM images of GNCs, PGNCs, pPGNCs, DOX\@PGNCs and DOX\@pPGNCs. Scale bar: 50 nm. **(C)** Temperature of PBS, GNCs, PGNCs, pPGNCs, DOX\@PGNCs and DOX\@pPGNCs upon 808 nm laser irradiation (0.7 W/cm^2^) for different time intervals. **(D)** Photothermal stability of DOX\@pPGNCs undergoing five cycles of 808 nm laser irradiation (0.7 W/cm^2^) and then cooling to room temperature. **(E)** Diameter of GNCs, PGNCs, pPGNCs, DOX\@PGNCs and DOX\@pPGNCs in response to 808 nm laser irradiation (0.7 W/cm^2^) for different time intervals. **(F)** *in vitro* DOX release profiles from DOX\@PGNCs and DOX\@pPGNCs in PBS with or without 808 nm laser irradiation (0.7 W/cm^2^) for 5 min. Black arrows indicate the irradiation points. The data are presented as the mean ± SD (n = 3).](thnov09p3825g004){#F4}

![**Cellular uptake and *in vitro* cytotoxicity of DOX\@pPGNCs. (A-D)** Intracellular Au content in MCF-7 **(A),** MCF-7/ADR **(B),** HepG2 **(C)** and HepG2/ADM cells **(D)** after treatment with DOX\@PGNCs or DOX\@pPGNCs at Au concentration of 10 µg/mL for 12 h at pH 7.4 or 6.5, respectively. **(E-F)** *in vitro* cytotoxicity against MCF-7 (E) or MCF-7/ADR cells (F) after treatment with PBS, free DOX, GNCs, PGNCs, pPGNCs, DOX\@PGNCs or DOX\@pPGNCs at DOX concentration of 1.2 μg/mL and Au concentration of 10 μg/mL at pH 7.4 or 6.5 for 24 h, respectively, followed with or without 808 nm laser irradiation (0.7 W/cm^2^) for 5 min and incubation for another 4 h. The data are presented as the mean ± SD (n = 3).](thnov09p3825g005){#F5}

![**NIR laser-triggered intracellular DOX release from DOX\@pPGNCs. (A)** Confocal microscopic images of MCF-7/ADR cells after treatment with DOX\@PGNCs or DOX\@pPGNCs at DOX concentration of 2 µg/mL for 4 h at pH 7.4 or 6.5, respectively, followed with or without 808 nm NIR laser irradiation (0.7 W/cm^2^) for 5 min. Scale bar: 50 µm. **(B, C)** Intracellular DOX content in MCF-7 (B) and MCF-7/ADR cells **(C)** after treatment with DOX\@PGNCs or DOX\@pPGNCs at DOX concentration of 2 µg/mL for 4 h at pH 7.4 or 6.5, respectively, followed with or without 808 nm NIR laser irradiation (0.7 W/cm^2^) for 5 min by flow cytometry. The data are presented as the mean ± SD (n = 3). \**P*\<0.05, \*\*\**P*\<0.001.](thnov09p3825g006){#F6}

![**NIR laser-induced tumor accumulation and deep tumor penetration in MCF-7/ADR tumor-bearing nude mice. (A)** DOX content in tumor and major organs including heart, liver, spleen, lung and kidney of MCF-7/ADR tumor-bearing mice at 24 h after intravenous injection of free DOX, DOX\@PGNCs or DOX\@pPGNCs at 2.4 mg DOX/kg dosage, followed with or without 808 nm laser irradiation (0.7 W/cm^2^) for 5 min. The data are presented as the mean ± SD (n = 3 mice for each group). \**P*\<0.05, \*\**P*\<0.01. **(B, C)** Colocalization of free DOX, DOX\@PGNCs or DOX\@pPGNCs (red) with FITC-CD31 antibody labeled endothelial cells (green) in tumor sections of MCF-7/ADR tumor-bearing mice at 24 h after intravenous administration of free DOX, DOX\@ING or DOX\@pPGNCs at 2.4 mg DOX/kg dosage, followed with or without 808 nm laser irradiation (0.7 W/cm^2^) for 5 min. scale bar is 50 μm. **(C)** The distribution of DOX fluorescence from tumor blood vessels to tumor tissues on the specified yellow line in B (n = 3 mice for each group).](thnov09p3825g007){#F7}

![***in vivo* photothermal effects of DOX\@pPGNCs. (A)** NIR laser-triggered temperature images of tumors recorded by an IR camera at 24 h after MCF-7/ADR tumor-bearing nude mice were intravenously injected with PBS, free DOX, GNCs, PGNCs, pPGNCs, DOX\@PGNCs or DOX\@pPGNCs at the Au dosage of 20 mg/kg, followed with 808 nm laser irradiation (0.7 W/cm^2^) for different time intervals. The data are presented as the mean ± SD (n = 3 mice for each group).](thnov09p3825g008){#F8}

![***In vivo* anticancer activity of DOX\@pPGNCs. (A)** Tumor growth curves of MCF-7/ADR tumor-bearing nude mice after intravenous injection of various formulations at the dosage of 20 mg/kg Au and 2.4 mg/kg DOX, followed with 808 nm laser irradiation (0.7 W/cm^2^) for 5 min at the tumor sites once every other day. **(B)** Photos of tumors after treatment. **(C)** Tumor weight after treatment. **(D)** Body weight change of MCF-7/ADR tumor-bearing nude mice after treatment as above. The data are presented as the mean ± SD (n = 5 mice for each group). \*\**P*\<0.01, \*\*\**P*\<0.001.](thnov09p3825g009){#F9}
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